Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) targeting ALK, MET, and ROS1 tyrosine kinases, has been approved for ALK-rearranged NSCLC in USA, European Union, China and other countries, with objective response rate (ORR) of proximately 60.8% and median progression-free survival (mPFS) of 9.7 months [29]. This evidence concerns the gene MET and non-small cell lung carcinoma.